<DOC>
	<DOCNO>NCT00086736</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , eflornithine , work different way stop tumor cell divide stop grow die . Androgens stimulate growth prostate cancer cell . Drugs use hormone therapy , bicalutamide , may fight prostate cancer stop adrenal gland produce androgen . Combining eflornithine bicalutamide may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness neoadjuvant eflornithine bicalutamide eflornithine alone , bicalutamide alone , neoadjuvant therapy treat patient undergo brachytherapy radical prostatectomy localized prostate cancer .</brief_summary>
	<brief_title>Neoadjuvant Eflornithine Bicalutamide Compared With Eflornithine Alone , Bicalutamide Alone , No Neoadjuvant Therapy Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy Radical Prostatectomy</brief_title>
	<detailed_description>OBJECTIVES : - Compare level polyamine spermine , polyamine putrescine , spermidine patient localized prostate cancer undergo brachytherapy radical prostatectomy treat neoadjuvant eflornithine bicalutamide v eflornithine alone vs bicalutamide alone vs neoadjuvant therapy . - Compare expression surrogate biomarkers ( i.e. , serum prostate-specific antigen , tissue level proliferate cell nuclear antigen , Ki67 , TGF-alpha , apoptosis assay [ ICH-PARP TUNEL ] , cytomorphometric index ) patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord Gleason score ( &lt; 7 v ≥ 7 ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral eflornithine oral bicalutamide daily . - Arm II : Patients receive oral eflornithine oral bicalutamide placebo daily . - Arm III : Patients receive oral eflornithine placebo oral bicalutamide daily . - Arm IV : Patients receive oral eflornithine placebo oral bicalutamide placebo daily . In arm , treatment continue 28 day absence unacceptable toxicity . Patients undergo either prostatectomy brachytherapy , determine patient , day 29 . Patients follow 4 week . PROJECTED ACCRUAL : A total 44 patient ( 11 per treatment arm ) accrue study within 11 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Localized disease Paraffin block diagnostic biopsy available Planning undergo brachytherapy prostatectomy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 10.0 g/dL WBC ≥ 3,500/mm^3 Platelet count ≥ 125,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL SGOT SGPT ≤ 2 time normal No history liver disease ( e.g. , hepatitis , cirrhosis , jaundice ) Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No symptomatic coronary artery disease No uncontrolled hypertension No acute myocardial infarction within past year Other Fertile patient must use effective contraception No 10 decibel baseline hearing loss frequency full bilateral audiometry within past month No hypersensitivity eflornithine bicalutamide No prior active malignancy except nonmelanoma skin cancer cancer curatively treat least 5 year ago evidence recurrent residual disease No concurrent acute chronic medical psychiatric condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No concurrent chemotherapy Endocrine therapy More 1 year since prior antiandrogen , luteinizing hormonereleasing hormone ( LHRH ) agonist , bicalutamide , finasteride , diethylstilbestrol No concurrent antiandrogen , LHRH agonist , finasteride , diethylstilbestrol Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>